August 6, 2026 FDA approves Replimune melanoma drug previously rejected twice Portfolio Company News Read more
July 29, 2026 Less than year after launch, Caldera lines up $278M financing and Nasdaq debut Portfolio Company News Read more
June 24, 2026 Novartis targets undruggable cancers with $1.9bn Antares Therapeutics deal Portfolio Company News Read more